Commentary on “A roadmap for the prevention of dementia II. Leon Thal Symposium 2008.” Centers of excellence in Alzheimer's disease: It is time to better integrate patient care and clinical research to improve the prevention and treatment of Alzheimer's d

2009 ◽  
Vol 5 (2) ◽  
pp. 133-136 ◽  
Author(s):  
Rachelle S. Doody
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Clinical Research ◽  
Patient Care ◽  
Centers Of Excellence ◽  
Prevention And Treatment

Synthesis of New Peptide Derivatives of Galanthamine Designed for Prevention and Treatment of Alzheimer’s Disease

2015 ◽  
Vol 22 (10) ◽  
pp. 913-922 ◽  
Author(s):  
Lyubomir Vezenkov ◽  
Lilia Ilieva ◽  
Dancho Danalev ◽  
Anastasia Bakalova ◽  
D. Vassilev ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Prevention And Treatment ◽  
Peptide Derivatives ◽  
Derivatives Of

Constructing a Local Potential Participant Registry to Improve Alzheimer’s Disease Clinical Research Recruitment

2018 ◽  
Vol 63 (3) ◽  
pp. 1055-1063 ◽  
Author(s):  
Joshua D. Grill ◽  
Dan Hoang ◽  
Daniel L. Gillen ◽  
Chelsea G. Cox ◽  
Adrijana Gombosev ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Clinical Research ◽  
Local Potential ◽  
Potential Participant ◽  
Research Recruitment

scholarly journals Use of curcumin in diagnosis, prevention, and treatment of Alzheimer's disease

2018 ◽  
Vol 13 (4) ◽  
pp. 742 ◽  
Author(s):  
Kun Zhang ◽  
Min Chen ◽  
Zhi-Yun Du ◽  
Xi Zheng ◽  
Dong-Li Li ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Prevention And Treatment

Alzheimer’s Disease: From Amyloid to Autoimmune Hypothesis

2020 ◽  
Vol 26 (5-6) ◽  
pp. 455-470
Author(s):  
Yuri I. Arshavsky
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Immune System ◽  
Pyramidal Neurons ◽  
Adaptive Immune System ◽  
Memory Formation ◽  
Autoimmune Response ◽  
Prevention And Treatment ◽  
Ad Prevention ◽  
Clinical Verification

Although Alzheimer’s disease (AD) was described over a century ago, there are no effective approaches to its prevention and treatment. Such a slow progress is explained, at least in part, by our incomplete understanding of the mechanisms underlying the pathogenesis of AD. Here, I champion a hypothesis whereby AD is initiated on a disruption of the blood-brain barrier (BBB) caused by either genetic or non-genetic risk factors. The BBB disruption leads to an autoimmune response against pyramidal neurons located in the allo- and neocortical structures involved in memory formation and storage. The response caused by the adaptive immune system is not strong enough to directly kill neurons but may be sufficient to make them selectively vulnerable to neurofibrillary pathology. This hypothesis is based on the recent data showing that memory formation is associated with epigenetic chromatin modifications and, therefore, may be accompanied by expression of memory-specific proteins recognized by the immune system as “non-self” antigens. The autoimmune hypothesis is testable, and I discuss potential ways for its experimental and clinical verification. If confirmed, this hypothesis can radically change therapeutic approaches to AD prevention and treatment.

scholarly journals Reduced memory and executive functioning significantly relates to participation in early phase clinical research in Alzheimer's disease

2020 ◽  
Vol 16 (S9) ◽  
Author(s):  
Lovingly Park ◽  
Lev Gertsik ◽  
Zyanya Mendoza ◽  
Lydia Morris ◽  
Claudia Aguilar ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Executive Functioning ◽  
Clinical Research ◽  
Early Phase
Sign in / Sign up

Export Citation Format

Share Document